Skip to main content

Phase I/II Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Niave patients with Recurrent WHO grade IV Malignant Glioma. Study#2

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Tactical Therapeutics, Inc.

Start Date

October 1, 2013

End Date

November 3, 2016
 

Administered By

Duke Cancer Institute

Awarded By

Tactical Therapeutics, Inc.

Start Date

October 1, 2013

End Date

November 3, 2016